Skip to content
Peptigraph home

AOD-9604 and Tirzepatide Together: What Is Known

AOD-9604 and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
HGH fragment analogNot FDA approved · research chemicalAOD-9604Fragment of human growth hormone studied only in animals; in rats, 19 days of oral treatment reduced body-weight gain by over 50%.[7]GLP-1 & metabolicGLP-1 / GIP dual agonistFDA approved (Mounjaro, Zepbound)TirzepatideFDA-approved dual GIP and GLP-1 receptor agonist; in a large trial, mean weight change at week 72 was -15.0% on 5-mg and -19.5% on 10-mg weekly doses.[14]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

AOD-9604 is not FDA approved, and we have no sourced data on combining it with Tirzepatide.
Each component

Side by side

Showing 11 of 13 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.

FieldAOD-9604Tirzepatide
ClassHGH fragment analogGLP-1 / GIP dual agonist
Also calledAODtirz, tirze, Mounjaro, Zepbound
FDA statusNot FDA approved · research chemicalFDA approved (Mounjaro, Zepbound)
WADAProhibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Anti-doping detection
  • AOD9604 can be detected in urine at 50 pg/mL; a stable serum metabolite may lengthen the detection window.PMID 25208511
  • Screening for a stable metabolite may allow a longer detection window (no duration was given).PMID 25208511
None reportedanti-doping literature, as of 2 Oct 2026
Half-lifeNo published half-life foundPubMed search, 11 Oct 2026approximately 5 dayssubcutaneous · FDA label (Mounjaro)
Evidence strengthAnimal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised24 human (22 randomized or controlled) of 30 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)

What each has been tested for

AOD-9604 weight data come from rodents: in a rat study, 19 days of oral AOD9604 cut body-weight gain by more than half versus controls.[7]

In obese mice, chronic AOD treatment reduced weight gain and was tied to fat oxidation and glycerol release, again an animal result.[16]

Tirzepatide has randomized human weight data: in SURMOUNT-5 it beat semaglutide head to head at week 72.[12]

Together

The dataset's PubMed search for this pair returned 0 records.

Calculated from pubmed query ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key aod-9604__tirzepatide); no arithmetic applied.

On the approved side, the Zepbound label says the drug delays gastric emptying.[17]

What the approved side warns about

Tirzepatide carries a boxed warning from rodent studies: it caused thyroid C-cell tumours in rats, and the human relevance is not determined.[17]

Where each stands

AOD-9604 has no FDA-approved product: the Drugs@FDA lookup for it returned no match.[18]

WADA's prohibited list names AOD-9604 as an example of a growth hormone fragment.[4]

Drugs@FDA lists tirzepatide as Mounjaro, a prescription product.[19]

Common questions

Can you take AOD-9604 with tirzepatide?

No study of the pair is cited here. The Zepbound label says tirzepatide delays gastric emptying.[17]

AOD 9604 vs tirzepatide: how do they compare on weight?

AOD-9604's weight data cited here are from rodents: in rats, 19 days of oral AOD9604 cut body-weight gain by over 50%. Tirzepatide has randomized human trial data.[7]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
  6. 6Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
  7. 7Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
  8. 8PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  11. 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
  12. 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  13. 13PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
  15. 15PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  16. 16Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
  17. 17ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  18. 18Drugs@FDA (openFDA) search: active ingredient "AOD-9604"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  19. 19Drugs@FDA (openFDA) search: active ingredient "tirzepatide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.